We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+13.03%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$260M
AUM Growth
+$4.09M
Cap. Flow
-$10.4M
Cap. Flow %
-3.98%
Top 10 Hldgs %
46.09%
Holding
68
New
5
Increased
11
Reduced
10
Closed
14

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$11.8M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$5.56M
3
ABMD
Abiomed Inc
ABMD
+$4.78M
4
INCY icon
Incyte
INCY
+$3.62M
5
XENT
Intersect ENT, Inc
XENT
+$2.94M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$11.9M
2
SAGE
Sage Therapeutics
SAGE
+$4.32M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$4.01M
4
GILD icon
Gilead Sciences
GILD
+$2.9M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$2.73M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.8B
$16.1M 6.17%
163,500
+9,500
+6% +$850K
CELG
2
DELISTED
Celgene Corp
CELG
$15.1M 5.78%
189,522
-16,000
-8% -$1.33M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$139B
$14.1M 5.43%
83,222
+15,000
+22% +$2.33M
ILMN icon
4
Illumina
ILMN
$34.3B
$12.6M 4.83%
+46,260
New +$11.8M
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$11.6M 4.47%
694,500
-157,000
-18% -$2.5M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$83.1B
$10.8M 4.15%
31,330
-4,700
-13% -$1.47M
BIIB icon
7
Biogen
BIIB
$32.7B
$10.5M 4.04%
36,208
-9,400
-21% -$2.64M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$10.1M 3.89%
81,641
+9,200
+13% +$1.08M
EXEL icon
9
Exelixis
EXEL
$13.7B
$9.57M 3.67%
444,534
+56,200
+14% +$1.16M
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$9.55M 3.67%
370,000
– –
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.6B
$9.16M 3.52%
97,284
+32,000
+49% +$2.8M
INCY icon
12
Incyte
INCY
$25.9B
$8.44M 3.24%
125,975
+53,000
+73% +$3.62M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$7.86M 3.02%
492,930
– –
LGND icon
14
Ligand Pharmaceuticals
LGND
$5.67B
$7.25M 2.78%
56,105
-11,221
-17% -$1.25M
HALO icon
15
Halozyme
HALO
$12.1B
$7.23M 2.78%
428,633
+70,000
+20% +$1.32M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$6.73M 2.58%
42,996
-27,500
-39% -$4.32M
GILD icon
17
Gilead Sciences
GILD
$185B
$6.4M 2.46%
90,284
-41,000
-31% -$2.9M
SPPI
18
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$6.29M 2.41%
+300,000
New +$5.56M
ABMD
19
DELISTED
Abiomed Inc
ABMD
$5.4M 2.07%
+13,200
New +$4.78M
IONS icon
20
Ionis Pharmaceuticals
IONS
$10.4B
$5.27M 2.02%
126,500
– –
SHPG
21
DELISTED
Shire pic
SHPG
$4.22M 1.62%
25,000
-74,000
-75% -$11.9M
XENT
22
DELISTED
Intersect ENT, Inc
XENT
$4.19M 1.61%
112,000
+75,000
+203% +$2.94M
ASXC
23
DELISTED
Asensus Surgical, Inc.
ASXC
$3.82M 1.47%
68,391
– –
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$31.6B
$3.62M 1.39%
36,800
– –
SRPT icon
25
Sarepta Therapeutics
SRPT
$2.28B
$3.57M 1.37%
27,000
– –
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2018 Portfolio in Review

As of Q2 2018, International Biotechnology Trust held 68 positions worth $260M, up 1.6% from $256M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

International Biotechnology Trust withdrew a net $10.4M in Q2 2018, closing 14 positions and reducing 10 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $4.01M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Illumina worth $12.6M.

  • International Biotechnology Trust's largest Q2 2018 buy was Illumina: 46,260 shares worth $12.6M.
  • International Biotechnology Trust added most to Incyte in Q2 2018, an estimated $3.62M increase.
  • International Biotechnology Trust's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.9M.
  • International Biotechnology Trust fully exited Clovis Oncology, Inc. in Q2 2018, selling an estimated $4.01M.
  • International Biotechnology Trust's ten largest holdings make up 46% of its $260M portfolio in Q2 2018.
  • International Biotechnology Trust opened 5 new positions and closed 14 in Q2 2018.
  • International Biotechnology Trust's portfolio value rose 1.6% quarter-over-quarter to $260M.

Based on International Biotechnology Trust's 13F filing for Q2 2018, filed 13 Aug 2018.